Literature DB >> 12227932

Effect of hyperthermia combined with external radiation therapy in primary non-small cell lung cancer with direct bony invasion.

H Sakurai1, K Hayakawa, N Mitsuhashi, Y Tamaki, Y Nakayama, H Kurosaki, S Nasu, H Ishikawa, J I Saitoh, T Akimoto, H Niibe.   

Abstract

PURPOSE: Local control in lung cancer directly invading the bone is extremely poor. Effects of regional hyperthermia combined with conventional external beam radiation therapy were evaluated.
MATERIALS AND METHODS: Thirteen patients with non-small lung cancer (NSCLC) with direct bony invasion were treated with hyperthermia plus irradiation (hyperthermia group). The treatment outcome was compared with the historical treatment results in 13 patients treated with external radiation therapy alone (radiation alone group). In patients with no distant metastasis, radiation therapy at a total dose of 60-70 Gy was administered to both groups. Hyperthermia was performed for 45-60 min immediately after irradiation for two-four sessions with radiofrequency capacitive heating devices.
RESULTS: For primary response, 10 of the 13 tumours responded to the treatment (3 CR, 7 PR) in the hyperthermia group, whereas seven tumours responded (1 CR, 6 PR) in the radiation alone group. The 2-year local recurrence-free survival rate for clinical M(0) patients in the hyperthermia group and that in the radiation alone group were 76.1 and 16.9%, respectively. Three patients died of distant metastases within 2 years in the hyperthermia group, but two out of three tumours histologically disappeared, even in the autopsy examination. The 2-year overall survival rate for clinical M(0) patients in the hyperthermia group and that in the radiation alone group were 44.4 and 15.4%, respectively. No severe pulmonary complication was observed in either group.
CONCLUSIONS: Regional hyperthermia combined with conventional irradiation could be a tool to improve local control in patients with NSCLC deeply invading the chest wall.

Entities:  

Mesh:

Year:  2002        PMID: 12227932     DOI: 10.1080/02656730210146917

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  7 in total

1.  Radiofrequency ablation in a previously irradiated liver.

Authors:  Marc A Friedman; Rosemary Altemus; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2003-10       Impact factor: 3.464

Review 2.  A novel hyperthermia treatment for bone metastases using magnetic materials.

Authors:  Akihiko Matsumine; Kenji Takegami; Kunihiro Asanuma; Takao Matsubara; Tomoki Nakamura; Atsumasa Uchida; Akihiro Sudo
Journal:  Int J Clin Oncol       Date:  2011-03-04       Impact factor: 3.402

3.  Equivalence of cell survival data for radiation dose and thermal dose in ablative treatments: analysis applied to essential tremor thalamotomy by focused ultrasound and gamma knife.

Authors:  D Schlesinger; M Lee; G Ter Haar; B Sela; M Eames; J Snell; N Kassell; J Sheehan; J M Larner; J-F Aubry
Journal:  Int J Hyperthermia       Date:  2017-01-31       Impact factor: 3.914

4.  Novel hyperthermia for metastatic bone tumors with magnetic materials by generating an alternating electromagnetic field.

Authors:  Akihiko Matsumine; Katsuyuki Kusuzaki; Takao Matsubara; Ken Shintani; Haruhiko Satonaka; Toru Wakabayashi; Shinichi Miyazaki; Katsuya Morita; Kenji Takegami; Atsumasa Uchida
Journal:  Clin Exp Metastasis       Date:  2007-05-09       Impact factor: 4.510

Review 5.  Current status of oncothermia therapy for lung cancer.

Authors:  Andras Szasz
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-04-10

Review 6.  Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

Authors:  Jan C Peeken; Peter Vaupel; Stephanie E Combs
Journal:  Front Oncol       Date:  2017-06-30       Impact factor: 6.244

Review 7.  Immunogenic Effect of Hyperthermia on Enhancing Radiotherapeutic Efficacy.

Authors:  Sungmin Lee; Beomseok Son; Gaeul Park; Hyunwoo Kim; Hyunkoo Kang; Jaewan Jeon; HyeSook Youn; BuHyun Youn
Journal:  Int J Mol Sci       Date:  2018-09-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.